Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.

Luigino CalzettaBeatrice Ludovica RitondoMaria Gabriella MateraFrancesco FaccioloRogliani Paola

Published in: British journal of pharmacology (2020)

Targeting the IL-5/IL-5Rα axis is an effective strategy to prevent the AHR. Benralizumab was more potent than the mepolizumab and the concentration-dependent beneficial effects of both these monoclonal antibodies were related to improved levels of cAMP in hyperresponsive airways.

Keyphrases

cancer therapy
cystic fibrosis
drug delivery
binding protein
anti inflammatory